Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

How do you choose which type of cell to use for my condition?

At Stem Cell Mexico, choosing the right cell therapy for your condition involves more than choosing a type of cell.

Free Consultation

Our cell product is exclusively allogeneic mesenchymal stromal cells (MSCs) from Wharton's jelly (umbilical cord tissue), and for each patient the doctor decides how to use it: the dose, the route of administration (direct injection, intravenous infusion or a combination), the exact targets, the image guidance, whether to combine cells with platelet-rich plasma (PRP) or other supportive components, and whether more than one session may be needed. These decisions are based on your diagnosis, the type and extent of tissue damage, whether blood supply or inflammation is a central problem, your overall health, your imaging and laboratory results, and your goals. Sometimes, the right decision is that cell therapy is not appropriate and another treatment should come first.

This guide walks you through how these decisions are made, so you can understand and question your own treatment plan.

Step 1: Clarify the diagnosis and the main problem

Before any decision about cells, the doctor needs to know exactly what is causing your symptoms. Two people with "back pain" may have a degenerated disc, an irritated facet joint, sacroiliac joint dysfunction or a compressed nerve. Two people with "memory problems" may have very different underlying conditions. The evaluation includes:

  • Your medical history and symptoms.
  • A review of imaging, such as MRI, X-ray, ultrasound or CT.
  • Laboratory tests.
  • Prior treatments and how you responded.

The goal is to identify the main pain generator or disease process, because the treatment plan must target it.

Step 2: Decide whether a local or systemic approach fits

Local problems

Conditions such as knee osteoarthritis, tendinopathy, ligament injuries or a degenerated disc involve a defined area. Cells are injected directly into or around the affected structure, so they act where they are needed. Lower total doses are usually sufficient.

Systemic or widespread problems

Conditions with a strong inflammatory or immune component, or that affect many areas, such as autoimmune conditions, neurological diseases or frailty, may be approached with intravenous (IV) infusion, which distributes the cells' signals throughout the body.

Combined approaches

Some patients benefit from both: for example, direct injection in the most affected joints plus an IV infusion for broader anti-inflammatory support.

Step 3: Choose the route and guidance

A review in Frontiers in Immunology (Caplan and colleagues, 2019) summarized how each route affects what happens to the cells:

  • IV infusion: easy and low risk, but many cells are temporarily trapped in the lungs before being cleared, so effects are largely systemic and signal-based.
  • Direct local injection: places cells precisely in the target tissue and keeps them there longer, with fewer cells lost to the lungs.
  • Intrathecal delivery (into the spinal fluid): studied for neurological conditions such as spinal cord injury and ALS, bypassing some barriers between the blood and the nervous system.
  • Intra-arterial delivery: brings cells closer to a target organ, with specific risks such as small vessel blockages.

For injections, the doctor also chooses the guidance method: ultrasound for joints, tendons and ligaments, and fluoroscopy for the spine, where precise needle placement is critical.

Step 4: Decide the dose

The dose depends on:

  • The size and number of targets: a small finger joint needs fewer cells than a knee or several spinal levels.
  • The route: systemic infusions use larger doses than local injections.
  • Body weight and health: especially for systemic protocols.
  • The severity of damage: but more is not always better. Too many cells in a confined space can increase inflammation and discomfort, and clinical studies in osteoarthritis have not shown a simple "more cells, more benefit" relationship.

Step 5: Consider the oxygen and blood supply environment

Some conditions involve poor blood flow or low oxygen in the tissue, for example ischemic heart disease, diabetic complications, peripheral artery disease or certain chronic wounds. In these cases, the ability of cells to support new small blood vessels (angiogenesis) becomes particularly relevant. Laboratory comparisons show that MSCs from different sources release different amounts of vascular and neurotrophic factors. A study in Scientific Reports (Petrenko and colleagues, 2020) found that bone marrow MSCs released more vascular endothelial growth factor (VEGF), while Wharton's jelly MSCs released more brain-derived neurotrophic factor, nerve growth factor and hepatocyte growth factor. These profiles help explain why researchers consider the cell source in relation to the problem being treated.

Step 6: Decide on complementary components

  • PRP: made from your own blood, it provides platelets and growth factors and is commonly combined with cells for musculoskeletal treatments.
  • Exosomes: cell-free vesicles released by MSCs, sometimes used in aesthetic or specific protocols. They are not living cells.
  • Supportive therapies: such as NAD+ when your doctor considers them appropriate.

Step 7: Plan follow-up and possible additional sessions

Some patients improve after a single application. Others may benefit from PRP sessions in the following months or from a second cell application after a period of evaluation. This should be decided based on your progress rather than a fixed package.

Two examples of how plans differ

Example 1: chronic shoulder pain. A 58-year-old with a partial rotator cuff tear and early shoulder arthritis is evaluated with MRI and ultrasound. The plan might include ultrasound-guided injections into the tendon tear, the joint and the subacromial space, combined with PRP and mild sedation, followed by a structured physical therapy program. An IV infusion would add little for a localized problem.

Example 2: multiple sclerosis with fatigue and walking difficulty. Here, the main issue is immune-mediated inflammation affecting the nervous system. The plan would rely on IV infusion at a dose based on body weight and health, with careful coordination with the patient's neurologist and disease-modifying therapy, and with progress measured using walking tests and fatigue scales.

Same cell product, very different plans. This is why a quote is never generated without a medical review.

Why cell source matters, and why we use umbilical cord MSCs

A review in Stem Cells Translational Medicine (Mastrolia and colleagues, 2019) highlights that MSC products vary with tissue source, donor characteristics and laboratory processing. These variations can affect how cells grow, what they release and how they behave in the body. For every protocol, Stem Cell Mexico uses Wharton's jelly MSCs because they come from a young, healthy source, grow efficiently to reach defined doses, can be tested and documented before release, and do not require a harvesting procedure. The decisions in Steps 2 to 7 are then tailored to your condition.

When cell therapy is not the right choice

A responsible evaluation sometimes concludes that cell therapy should not be done now, or at all. Examples include:

  • A complete tendon or ligament rupture that needs surgical repair.
  • Severe joint destruction where joint replacement is likely to provide better results.
  • Nerve compression with progressive weakness, which requires urgent evaluation.
  • Active infection, uncontrolled medical conditions or cancer within the past five years.
  • A condition for which there is no reasonable biological basis to expect benefit.

In these situations, your doctor should explain why and suggest appropriate alternatives.

How you can help your doctor choose well

The more precise the information, the better the plan. Before your consultation, gather recent imaging (with reports and, ideally, the images themselves), laboratory results, a list of medications and supplements, notes from specialists and a short description of your main goals, such as walking a certain distance without pain or returning to a specific sport. Mention previous injections or surgeries and how you responded. This allows the doctor to target the right structures and to define clear, measurable goals from the beginning.

What the evidence says

Evidence for MSC therapy differs by condition, route and dose:

  • Strongest evidence: knee osteoarthritis and degenerative disc disease with direct injection.
  • Growing evidence: neurological, cardiac and autoimmune conditions, often with IV delivery.
  • Early: many wellness and anti-aging uses.

The science also continues to evolve on optimal dose and route. That is why each plan should be explained, documented and reviewed with you.

What this means for you

Your treatment plan should answer clearly: what is being treated, how the cells will be delivered, how many cells, why that combination, and how results will be measured. If any of these points are unclear, ask.

Questions to ask during your evaluation

  • What is the main cause of my symptoms, and how will the treatment target it?
  • Why this route and this dose?
  • Will PRP or other components be included, and why?
  • How will we know whether it worked?
  • Are there reasons cell therapy might not be right for me?

Bottom line

Choosing the right cell therapy means matching a well-characterized cell product to your diagnosis through the right dose, route, targets and complementary components. At Stem Cell Mexico, we use Wharton's jelly MSCs and tailor how they are delivered to each patient. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your condition, goals and medical history.

References

  1. Mastrolia I et al. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. Stem Cells Translational Medicine, 2019 (opens in a new tab)
  2. Petrenko Y et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Scientific Reports, 2020 (opens in a new tab)
  3. Caplan H, Olson SD, Cox CS Jr et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019 (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation